Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …

Heterogeneity within a tumour increases its ability to adapt to constantly changing
constraints, but adversely affects a patient's prognosis, therapy response and clinical …

Cancer develops through a process of somatic evolution1, 2. Sequencing data from a single
biopsy represent a snapshot of this process that can reveal the timing of specific genomic …

Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion
and resistance to therapy. Here, using paired whole-exome and RNA sequencing data, we …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …